These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 27806433)

  • 1. Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies.
    Roberts AW; Huang D
    Clin Pharmacol Ther; 2017 Jan; 101(1):89-98. PubMed ID: 27806433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
    Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
    Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutics targeting Bcl-2 in hematological malignancies.
    Ruefli-Brasse A; Reed JC
    Biochem J; 2017 Oct; 474(21):3643-3657. PubMed ID: 29061914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A BH3 Mimetic for Killing Cancer Cells.
    Green DR
    Cell; 2016 Jun; 165(7):1560. PubMed ID: 27315468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.
    Roberts AW; Stilgenbauer S; Seymour JF; Huang DCS
    Clin Cancer Res; 2017 Aug; 23(16):4527-4533. PubMed ID: 28100580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies.
    Yalniz FF; Wierda WG
    Drugs; 2019 Aug; 79(12):1287-1304. PubMed ID: 31313099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.
    Moia R; Diop F; Favini C; Kodipad AA; Gaidano G
    Expert Rev Hematol; 2018 May; 11(5):391-402. PubMed ID: 29561706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment.
    Vogler M; Walter HS; Dyer MJS
    Br J Haematol; 2017 Aug; 178(3):364-379. PubMed ID: 28449207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
    King AC; Peterson TJ; Horvat TZ; Rodriguez M; Tang LA
    Ann Pharmacother; 2017 May; 51(5):410-416. PubMed ID: 28056525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic targeting of apoptosis in chronic lymphocytic leukemia.
    Ahn IE; Davids MS
    Semin Hematol; 2024 Apr; 61(2):109-118. PubMed ID: 38538512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venetoclax (Venclexta) for chronic lymphocytic leukemia.
    Med Lett Drugs Ther; 2016 Aug; 58(1500):101-2. PubMed ID: 27466751
    [No Abstract]   [Full Text] [Related]  

  • 13. BCL2 and miR-15/16: from gene discovery to treatment.
    Pekarsky Y; Balatti V; Croce CM
    Cell Death Differ; 2018 Jan; 25(1):21-26. PubMed ID: 28984869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia.
    Besbes S; Pocard M; Mirshahi M; Billard C
    Crit Rev Oncol Hematol; 2016 Apr; 100():32-6. PubMed ID: 26899021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venetoclax for the treatment of patients with chronic lymphocytic leukemia.
    Crombie J; Davids MS
    Future Oncol; 2017 Jun; 13(14):1223-1232. PubMed ID: 28492339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venetoclax: A new wave in hematooncology.
    Mihalyova J; Jelinek T; Growkova K; Hrdinka M; Simicek M; Hajek R
    Exp Hematol; 2018 May; 61():10-25. PubMed ID: 29477371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.
    Anderson MA; Deng J; Seymour JF; Tam C; Kim SY; Fein J; Yu L; Brown JR; Westerman D; Si EG; Majewski IJ; Segal D; Heitner Enschede SL; Huang DC; Davids MS; Letai A; Roberts AW
    Blood; 2016 Jun; 127(25):3215-24. PubMed ID: 27069256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic development and current uses of BCL-2 inhibition.
    Roberts AW
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):1-9. PubMed ID: 33275682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors.
    Thijssen R; Slinger E; Weller K; Geest CR; Beaumont T; van Oers MH; Kater AP; Eldering E
    Haematologica; 2015 Aug; 100(8):e302-6. PubMed ID: 25957396
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting BCL2 for the treatment of lymphoid malignancies.
    Anderson MA; Huang D; Roberts A
    Semin Hematol; 2014 Jul; 51(3):219-27. PubMed ID: 25048785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.